JP6426618B2 - 新規なピリジン誘導体 - Google Patents

新規なピリジン誘導体 Download PDF

Info

Publication number
JP6426618B2
JP6426618B2 JP2015545757A JP2015545757A JP6426618B2 JP 6426618 B2 JP6426618 B2 JP 6426618B2 JP 2015545757 A JP2015545757 A JP 2015545757A JP 2015545757 A JP2015545757 A JP 2015545757A JP 6426618 B2 JP6426618 B2 JP 6426618B2
Authority
JP
Japan
Prior art keywords
pyridine
cyclopropylmethoxy
carboxylic acid
amide
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015545757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501240A5 (cg-RX-API-DMAC7.html
JP2016501240A (ja
Inventor
フライ，ベアト
ゴッビ，ルカ
グレター，ウーヴェ
篤 金原
篤 金原
ネッテコフェン，マティアス
レーヴァー，シュテファン
ロジャース−エバンス，マーク
シュルツ−ガーシュ，ターニャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2016501240A publication Critical patent/JP2016501240A/ja
Publication of JP2016501240A5 publication Critical patent/JP2016501240A5/ja
Application granted granted Critical
Publication of JP6426618B2 publication Critical patent/JP6426618B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2015545757A 2012-12-07 2013-12-02 新規なピリジン誘導体 Expired - Fee Related JP6426618B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12196022 2012-12-07
EP12196022.3 2012-12-07
PCT/EP2013/075225 WO2014086705A1 (en) 2012-12-07 2013-12-02 Novel pyridine derivatives

Publications (3)

Publication Number Publication Date
JP2016501240A JP2016501240A (ja) 2016-01-18
JP2016501240A5 JP2016501240A5 (cg-RX-API-DMAC7.html) 2017-01-19
JP6426618B2 true JP6426618B2 (ja) 2018-11-21

Family

ID=47290804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545757A Expired - Fee Related JP6426618B2 (ja) 2012-12-07 2013-12-02 新規なピリジン誘導体

Country Status (33)

Country Link
US (1) US9522886B2 (cg-RX-API-DMAC7.html)
EP (2) EP3357918A1 (cg-RX-API-DMAC7.html)
JP (1) JP6426618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150092282A (cg-RX-API-DMAC7.html)
CN (2) CN107674061A (cg-RX-API-DMAC7.html)
AR (1) AR093843A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013354278B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015012919A2 (cg-RX-API-DMAC7.html)
CA (1) CA2890100A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015001536A1 (cg-RX-API-DMAC7.html)
CO (1) CO7350620A2 (cg-RX-API-DMAC7.html)
CR (1) CR20150250A (cg-RX-API-DMAC7.html)
DK (1) DK2928881T3 (cg-RX-API-DMAC7.html)
EA (1) EA026669B1 (cg-RX-API-DMAC7.html)
ES (1) ES2668690T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180672T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036911T2 (cg-RX-API-DMAC7.html)
IL (1) IL239075B (cg-RX-API-DMAC7.html)
LT (1) LT2928881T (cg-RX-API-DMAC7.html)
MA (1) MA38239A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015007155A (cg-RX-API-DMAC7.html)
NO (1) NO2928881T3 (cg-RX-API-DMAC7.html)
PE (1) PE20151025A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501083B1 (cg-RX-API-DMAC7.html)
PL (1) PL2928881T3 (cg-RX-API-DMAC7.html)
PT (1) PT2928881T (cg-RX-API-DMAC7.html)
RS (1) RS57143B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201800170YA (cg-RX-API-DMAC7.html)
SI (1) SI2928881T1 (cg-RX-API-DMAC7.html)
TW (1) TWI600645B (cg-RX-API-DMAC7.html)
UA (1) UA114656C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014086705A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503969B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2964646B1 (en) 2013-03-07 2017-04-19 F. Hoffmann-La Roche AG Novel pyrazol derivatives
CA2899168A1 (en) 2013-03-26 2014-10-02 F. Hoffmann-La Roche Ag Novel pyridine derivatives
ES2635632T3 (es) 2013-05-02 2017-10-04 F. Hoffmann-La Roche Ag Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor CB2
PT2991987T (pt) 2013-05-02 2018-07-13 Hoffmann La Roche Derivados de purina como agonistas do recetor cb2
CA2915766C (en) 2013-09-06 2023-09-26 F. Hoffmann-La Roche Ag Triazolo[4,5-d]pyrimidine derivatives and their use as cannabinoid receptor 2 agonists
KR20160132495A (ko) * 2014-04-04 2016-11-18 에프. 호프만-라 로슈 아게 카나비노이드 수용체 작용제로서 5,6-이치환된 피리딘-2-카복스아미드
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
DK3386951T3 (en) * 2015-12-09 2020-04-27 Hoffmann La Roche Phenylderivater som cannabinoidreceptor-2-agonister
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3642200B1 (en) 2017-06-20 2023-05-03 F. Hoffmann-La Roche AG Pyridine derivatives
CN112041309A (zh) * 2018-04-18 2020-12-04 巴斯夫欧洲公司 D-葡糖二酸-6,3-内酯单酯及其制备方法
CN112074513B (zh) 2018-06-27 2024-06-14 豪夫迈·罗氏有限公司 作为优先大麻素2激动剂的吡啶和吡嗪衍生物
JP7478672B2 (ja) * 2018-06-27 2024-05-07 エフ． ホフマン－ラ ロシュ アーゲー カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
MA53002A (fr) 2018-06-27 2021-05-05 Eth Zuerich Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2
EP3813888B1 (en) 2018-06-27 2025-11-26 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
EP4038055A1 (en) * 2019-09-30 2022-08-10 F. Hoffmann-La Roche AG Substituted 3,4-dihydroquinazoline for the treatment and prophylaxis of hepatitis b virus infection
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
EP4326257A4 (en) 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003316A (es) 2006-10-04 2009-04-09 Hoffmann La Roche Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
HK1208031A1 (en) 2016-02-19
HUE036911T2 (hu) 2018-08-28
SI2928881T1 (en) 2018-07-31
LT2928881T (lt) 2018-06-11
RS57143B1 (sr) 2018-07-31
US20150307452A1 (en) 2015-10-29
MA38239A1 (fr) 2017-03-31
US9522886B2 (en) 2016-12-20
CA2890100A1 (en) 2014-06-12
CN107674061A (zh) 2018-02-09
DK2928881T3 (en) 2018-05-28
EP2928881A1 (en) 2015-10-14
CR20150250A (es) 2015-06-11
MX2015007155A (es) 2015-10-14
TW201427951A (zh) 2014-07-16
ES2668690T3 (es) 2018-05-21
AR093843A1 (es) 2015-06-24
CL2015001536A1 (es) 2015-10-23
CO7350620A2 (es) 2015-08-10
AU2013354278A1 (en) 2015-05-14
EA026669B1 (ru) 2017-05-31
KR20150092282A (ko) 2015-08-12
NO2928881T3 (cg-RX-API-DMAC7.html) 2018-08-11
PL2928881T3 (pl) 2018-07-31
PE20151025A1 (es) 2015-07-15
PT2928881T (pt) 2018-05-07
IL239075A0 (en) 2015-07-30
IL239075B (en) 2018-11-29
CN104837831B (zh) 2017-10-31
ZA201503969B (en) 2016-04-28
SG11201504416XA (en) 2015-07-30
EP3357918A1 (en) 2018-08-08
WO2014086705A1 (en) 2014-06-12
PH12015501083A1 (en) 2015-08-03
BR112015012919A2 (pt) 2017-07-11
JP2016501240A (ja) 2016-01-18
UA114656C2 (uk) 2017-07-10
EP2928881B1 (en) 2018-03-14
HRP20180672T1 (hr) 2018-06-01
PH12015501083B1 (en) 2015-08-03
SG10201800170YA (en) 2018-02-27
AU2013354278B2 (en) 2017-10-12
CN104837831A (zh) 2015-08-12
AU2017279648A1 (en) 2018-01-18
EA201591064A1 (ru) 2015-09-30
TWI600645B (zh) 2017-10-01

Similar Documents

Publication Publication Date Title
JP6426618B2 (ja) 新規なピリジン誘導体
JP6484746B2 (ja) Ｃｂ２アゴニストとして有用なピリジン−２−アミド
CA2735764C (en) 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP6322646B2 (ja) Ｃｂ２受容体アゴニストとしての新規ピラジン誘導体
TWI617551B (zh) 新穎吡啶衍生物
JP7445610B2 (ja) 医療に有用な新規化合物
JP6654574B2 (ja) Ｃｂ２アゴニストとして有用なピリジン−２−アミド
JP2022003066A (ja) カンナビノイド受容体２アゴニストとしてのフェニル誘導体
JP7454512B2 (ja) 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
JP7478672B2 (ja) カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物
JPWO2020002270A5 (cg-RX-API-DMAC7.html)
TW201326139A (zh) 新穎吡□衍生物
HK1208031B (en) Novel pyridine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20180116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181025

R150 Certificate of patent or registration of utility model

Ref document number: 6426618

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees